Twenty years ago, when invited to a social gathering, it seems like you could slap together any gluten-packed, dairy-dusted casserole and call it good. These days, however, it can feel like the “luck” in your neighbourhood potluck refers to your chances of accidentally baking up a disaster for a food allergy sufferer. You may have even experienced it yourself: Something you used to eat with blissful abandon now troubles your tummy or causes you to break out in hives.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.